JO3709B1 - تركيبة صيدلانية أو مجموعة طبية للاستخدام في علاج سرطان لدى كائن ثديي تتضمن إنزيم الأسباراجيناز وإنزيم الميثيونيناز - Google Patents

تركيبة صيدلانية أو مجموعة طبية للاستخدام في علاج سرطان لدى كائن ثديي تتضمن إنزيم الأسباراجيناز وإنزيم الميثيونيناز

Info

Publication number
JO3709B1
JO3709B1 JOP/2016/0276A JOP20160276A JO3709B1 JO 3709 B1 JO3709 B1 JO 3709B1 JO P20160276 A JOP20160276 A JO P20160276A JO 3709 B1 JO3709 B1 JO 3709B1
Authority
JO
Jordan
Prior art keywords
methioninase
asparaginase
mammal
kit
pharmaceutical composition
Prior art date
Application number
JOP/2016/0276A
Other languages
English (en)
Inventor
Karine Aguera
Yann Godfrin
Willy Berlier
Fabien Gay
Original Assignee
Erytech Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Erytech Pharma filed Critical Erytech Pharma
Application granted granted Critical
Publication of JO3709B1 publication Critical patent/JO3709B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/54—Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01001—Asparaginase (3.5.1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y404/00—Carbon-sulfur lyases (4.4)
    • C12Y404/01—Carbon-sulfur lyases (4.4.1)
    • C12Y404/01011—Methionine gamma-lyase (4.4.1.11)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Botany (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

يتعلق الاختراع بطريقة جديدة لمعالجة السرطانات السائلة والصلبة في حيوان ثديي ، بما في ذلك الإنسان ، حيث يتم إعطاء ميثيونيناز قبل الأسباراجيناز. يشمل الاختراع أيضًا استخدام الحرمان الغذائي من الميثيونين ، وربما يتم دمجه مع إعطاء الميثيونيناز ، قبل معالجة الأسباراجيناز. يمكن استخدام ميثيونيناز وأسباراجيناز على وجه الخصوص في شكل حر أو شكل مرتبط أو مغلف في كريات الدم الحمراء. شكل 1
JOP/2016/0276A 2015-12-31 2016-12-27 تركيبة صيدلانية أو مجموعة طبية للاستخدام في علاج سرطان لدى كائن ثديي تتضمن إنزيم الأسباراجيناز وإنزيم الميثيونيناز JO3709B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15307197.2A EP3187190A1 (en) 2015-12-31 2015-12-31 Method of treating a mammal, including human, against cancer using methionine and asparagine depletion

Publications (1)

Publication Number Publication Date
JO3709B1 true JO3709B1 (ar) 2021-01-31

Family

ID=55079994

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2016/0276A JO3709B1 (ar) 2015-12-31 2016-12-27 تركيبة صيدلانية أو مجموعة طبية للاستخدام في علاج سرطان لدى كائن ثديي تتضمن إنزيم الأسباراجيناز وإنزيم الميثيونيناز

Country Status (16)

Country Link
US (2) US11141468B2 (ar)
EP (2) EP3187190A1 (ar)
JP (1) JP6966451B2 (ar)
KR (1) KR102268259B1 (ar)
CN (1) CN108472339B (ar)
AU (1) AU2017204678B2 (ar)
BR (1) BR112018013227A2 (ar)
CA (1) CA3009918C (ar)
ES (1) ES2881787T3 (ar)
HK (1) HK1256155A1 (ar)
IL (1) IL260278B (ar)
JO (1) JO3709B1 (ar)
MX (1) MX2018007933A (ar)
RU (1) RU2733389C2 (ar)
SG (1) SG11201805311XA (ar)
WO (1) WO2017114966A1 (ar)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6702866B2 (ja) 2013-11-18 2020-06-03 ルビウス セラピューティクス， インコーポレイテッド 合成膜−レシーバー複合体
FR3017299B1 (fr) * 2014-02-12 2018-05-18 Erytech Pharma Composition pharmaceutique comprenant des erythrocytes encapsulant une enzyme a plp et son cofacteur
WO2015153102A1 (en) 2014-04-01 2015-10-08 Rubius Therapeutics, Inc. Methods and compositions for immunomodulation
EP3187190A1 (en) * 2015-12-31 2017-07-05 Erytech Pharma Method of treating a mammal, including human, against cancer using methionine and asparagine depletion
SG11201805253SA (en) 2016-01-11 2018-07-30 Rubius Therapeutics Inc Compositions and methods related to multimodal therapeutic cell systems for cancer indications
JP7176921B2 (ja) 2017-10-19 2022-11-22 アンチキャンサー インコーポレーテッド 癌治療、予防及びアンチエイジングのための組み換えメチオニナーゼを含む製剤
US20220362357A1 (en) 2018-08-31 2022-11-17 Stichting Radboud Universitair Medisch Centrum Synergistic Combinations of Amino Acid Depletion Agent Sensitizers (AADAS) and Amino Acid Depletion Agents (AADA), and Therapeutic Methods of Use Thereof
SG11202104205XA (en) * 2018-10-26 2021-05-28 Univ Texas Engineered primate cystine/cysteine degrading enzymes for therapeutic uses
WO2020099592A1 (en) * 2018-11-15 2020-05-22 Erytech Pharma Synergistic combinations of methionine depletion agents and immune checkpoint modulators
EP4149440A1 (en) 2020-05-11 2023-03-22 Erytech Pharma Red cell extracellular vesicles (rcevs) containing cargoes and methods of use and production thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5715835A (en) * 1992-11-19 1998-02-10 Anticancer, Inc. Methods for treating and reducing the potential for cardiovascular disease using methioninase compositions
US5891704A (en) * 1992-11-19 1999-04-06 Anticancer, Inc. Method to produce high levels of methioninase
US6017962A (en) * 1997-02-27 2000-01-25 Board Of Regents, The University Of Texas System Method of depletion of methionine in plasma and solid tumors and uses thereof
DE69837005T2 (de) 1997-03-13 2007-11-15 Anticancer Inc., San Diego Verfahren zur herstellung von kristallen der l-methionin-gamma-lyase
CN101579362A (zh) * 1999-10-04 2009-11-18 维昂药品公司 用于将效应分子定向递送至肿瘤的组合物及方法
EP1487436A4 (en) * 2002-03-08 2009-06-03 Signal Pharm Inc POLYTHERAPY FOR TREATING, PREVENTING OR MANAGING PROLIFERATIVE DISORDERS AND CANCERS
CA2492103A1 (en) * 2002-05-10 2004-05-27 The Ohio State University Flavin n-oxides: new anti-cancer agents and pathogen eradication agents
US20050234009A1 (en) * 2004-03-29 2005-10-20 Johnson Candace S Method of treating solid tumors and leukemias using combination therapy of vitamin D and anti-metabolic nucleoside analogs
FR2873925B1 (fr) 2004-08-05 2006-10-13 Erytech Pharma Soc Par Actions Procede et dispositif de lyse-rescellement pour l'incorporation de principe actif notamment asparaginase ou inositol hexaphosphate, dans des erythrocytes
US20100284982A1 (en) * 2007-12-20 2010-11-11 Yang Victor C Erythrocyte-encapsulated L-asparaginase for enhanced acute lymphoblastic leukemia therapy
US20150086521A1 (en) 2012-03-21 2015-03-26 Erytech Pharma Medicament for the Treatment of Acute Myeloid Leukemia (AML)
WO2013151774A1 (en) * 2012-04-04 2013-10-10 Halozyme, Inc. Combination therapy with an anti - hyaluronan agent and a tumor - targeted taxane
FR3005420B1 (fr) 2013-05-07 2015-09-18 Erytech Pharma Procede de stabilisation de suspensions d'erythrocytes encapsulant un principe actif, suspensions obtenues.
EP3046550B1 (en) * 2013-09-17 2020-04-15 The Regents of the University of California Enzyme-encapsulated nanoparticle platform
FR3017299B1 (fr) 2014-02-12 2018-05-18 Erytech Pharma Composition pharmaceutique comprenant des erythrocytes encapsulant une enzyme a plp et son cofacteur
EP3187190A1 (en) * 2015-12-31 2017-07-05 Erytech Pharma Method of treating a mammal, including human, against cancer using methionine and asparagine depletion

Also Published As

Publication number Publication date
JP6966451B2 (ja) 2021-11-17
RU2018123666A (ru) 2019-12-31
RU2018123666A3 (ar) 2020-02-26
ES2881787T3 (es) 2021-11-30
RU2733389C2 (ru) 2020-10-01
HK1256155A1 (zh) 2019-09-13
US11141468B2 (en) 2021-10-12
JP2019500386A (ja) 2019-01-10
US20190000941A1 (en) 2019-01-03
SG11201805311XA (en) 2018-07-30
CA3009918C (en) 2024-01-02
US20220040272A1 (en) 2022-02-10
EP3187190A1 (en) 2017-07-05
BR112018013227A2 (pt) 2018-12-04
CN108472339A (zh) 2018-08-31
MX2018007933A (es) 2018-08-09
AU2017204678A1 (en) 2018-07-12
CN108472339B (zh) 2022-02-15
KR20180097596A (ko) 2018-08-31
IL260278B (en) 2022-03-01
EP3397272B1 (en) 2021-06-23
EP3397272A1 (en) 2018-11-07
IL260278A (en) 2018-07-31
AU2017204678B2 (en) 2021-12-09
WO2017114966A1 (en) 2017-07-06
CA3009918A1 (en) 2017-07-06
KR102268259B1 (ko) 2021-06-24

Similar Documents

Publication Publication Date Title
JO3709B1 (ar) تركيبة صيدلانية أو مجموعة طبية للاستخدام في علاج سرطان لدى كائن ثديي تتضمن إنزيم الأسباراجيناز وإنزيم الميثيونيناز
MX2021013830A (es) Inhibidores de ezh2 para tratar linfomas.
PH12018502634A1 (en) Topical compositions of apremilast
MX2020008258A (es) Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos.
PH12019500845A1 (en) Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof
IN2015DN00376A (ar)
MX2017014338A (es) Seleccion dirigida de pacientes para el tratamiento con derivados de cortistatina.
SG10201902664RA (en) Combination therapy for treating cancer
MX2023000796A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
MX2022011334A (es) Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert.
NZ630367A (en) Methods of treatment of pediatric solid tumor
WO2016043874A3 (en) Combination therapy for treating cancer
MX2021002321A (es) Nuevos metodos.
MX2017006938A (es) Terapia de combinacion para el tratamiento de cancer.
MX2023005628A (es) Metodos para aumentar y/o estabilizar la funcion cardiaca en pacientes con enfermedad de fabry.
MX2018008645A (es) Derivados de 8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano.
PE20151751A1 (es) Metodos de tratamiento de la deficiencia de hierro con pirofosfato ferrico soluble
PE20181332A1 (es) Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos
MX2019009952A (es) Formulaciones de evolocumab de baja viscosidad y alta concentracion y metodos de elaboracion de las mismas.
RU2018107930A (ru) Агонисты tlr4, их композиции и применение для лечения рака
NZ745187A (en) 3-(carboxyethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
PH12020550462A1 (en) Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same
MX2016016400A (es) Formulaciones de oximetazolina estabilizadas y sus usos.
MX2016008027A (es) Uso de laquinimod para retrasar la evolucion de la enfermedad de huntington.
PH12021551235A1 (en) Elacestrant in combination with abemaciclib in women with breast cancer